| 1 |
DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes[J]. Lancet, 2018, 391(10138):2449-2462.
|
| 2 |
刘颖, 肖平, 陈焕伟. 胰岛移植治疗1型糖尿病的现状和未来[J]. 器官移植, 2019, 10(1):91-93.
|
| 3 |
Vantyghem MC, Chetboun M, Gmyr V, et al. Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: a prospective parallel-arm cohort study[J]. Diabetes Care, 2019, 42(11): 2042-2049.
|
| 4 |
Barton FB, Rickels MR, Alejandro R, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010[J]. Diabetes Care, 2012, 35(7): 1436-1445.
|
| 5 |
Lindahl JP, Reinholt FP, Eide IA, et al. In patients with type 1 diabetes simultaneous pancreas and kidney transplantation preserves long-term kidney graft ultrastructure and function better than transplantation of kidney alone[J]. Diabetologia, 2014, 57(11):2357-2365.
|
| 6 |
Sánchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs[J]. Gastroenterology, 2011, 140(1):51-64.
|
| 7 |
Sutherland DE, Sibley R, Xu XZ, et al. Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of typeⅠdiabetes[J]. Trans Assoc Am Physicians, 1984, 97:80-87.
|
| 8 |
Sibley RK, Sutherland DE, Goetz F, et al. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases[J]. Lab Invest, 1985, 53(2):132-144.
|
| 9 |
Vendrame F, Hopfner YY, Diamantopoulos S, et al. Risk factors for type 1 diabetes recurrence in immunosuppressed recipients of simultaneous pancreas-kidney transplants[J]. Am J Transplant, 2016, 16(1):235-245.
|
| 10 |
Viglietta V, Kent SC, Orban T, et al. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes[J]. J Clin Invest, 2002, 109(7):895-903.
|
| 11 |
Danke NA, Yang J, Greenbaum C, et al. Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects[J]. J Autoimmun, 2005, 25(4):303-311.
|
| 12 |
Spanier JA, Sahli NL, Wilson JC, et al. Increased effector memory insulin-specific CD4+ T cells correlate with insulin autoantibodies in patients with recent-onset type 1 diabetes[J]. Diabetes, 2017, 66(12): 3051-3060.
|
| 13 |
Monti P, Scirpoli M, Rigamonti A, et al. Evidence for in vivo primed and expanded autoreactive T cells as a specific feature of patients with type 1 diabetes[J]. J Immunol, 2007, 179(9):5785-5792.
|
| 14 |
Monti P, Piemonti L. Homeostatic T cell proliferation after islet transplantation[J]. Clin Dev Immunol, 2013, 2013:217934.
|
| 15 |
Abreu JR, Roep BO. Immune monitoring of islet and pancreas transplant recipients[J]. Curr Diab Rep, 2013, 13(5):704-712.
|
| 16 |
Monti P, Vignali D, Piemonti L. Monitoring inflammation, humoral and cell-mediated immunity in pancreas and islet transplants[J]. Curr Diabetes Rev, 2015, 11(3):135-143.
|
| 17 |
Martins LS. Autoimmune diabetes recurrence should be routinely monitored after pancreas transplantation[J]. World J Transplant, 2014, 4(3):183-187.
|
| 18 |
Korutla L, Rickels MR, Hu RW, et al. Noninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation[J]. Am J Transplant, 2019, 19(6):1852-1858.
|
| 19 |
Toso C, Isse K, Demetris AJ, et al. Histologic graft assessment after clinical islet transplantation[J]. Transplantation, 2009, 88(11):1286-1293.
|
| 20 |
Rickels MR, Stock PG, de Koning EJP, et al. Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop[J]. Transplantation, 2018, 102(9):1479-1486.
|
| 21 |
Wenzlau JM, Hutton JC. Novel diabetes autoantibodies and prediction of type 1 diabetes[J]. Curr Diab Rep, 2013, 13(5):608-615.
|
| 22 |
Braghi S, Bonifacio E, Secchi A, et al. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes[J]. Diabetes, 2000, 49(2):218-224.
|
| 23 |
Huurman VA, Hilbrands R, Pinkse GG, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation[J]. PLoS One, 2008, 3(6):e2435.
|
| 24 |
Martins LS, Henriques AC, Fonseca IM, et al. Pancreatic autoantibodies after pancreas-kidney transplantation-do they matter?[J]. Clin Transplant, 2014, 28(4):462-469.
|
| 25 |
Occhipinti M, Lampasona V, Vistoli F, et al. Zinc transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant[J]. Transplantation, 2011, 92(6):674-677.
|
| 26 |
Piemonti L, Everly MJ, Maffi P, et al. Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes[J]. Diabetes, 2013, 62(5):1656-1664.
|
| 27 |
Hilbrands R, Huurman VA, Gillard P, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients[J]. Diabetes, 2009, 58(10):2267-2276.
|
| 28 |
Bosi E, Braghi S, Maffi P, et al. Autoantibody response to islet transplantation in type 1 diabetes[J]. Diabetes, 2001, 50(11):2464-2471.
|
| 29 |
Argente-Pla M, Martínez-Millana A, Del Olmo-García MI, et al. Autoimmune diabetes recurrence after pancreas transplantation: diagnosis, management, and literature review[J]. Ann Transplant, 2019, 24:608-616.
|
| 30 |
Pestana N, Malheiro J, Silva F, et al. Impact of pancreatic autoantibodies in pancreas graft survival after pancreas-kidney transplantation[J]. Transplant Proc, 2020, 52(5):1370-1375.
|
| 31 |
Rodelo-Haad C, Agüera ML, Carmona A, et al. Pancreatic autoantibodies and CD14+ CD16+ monocytes subset are associated with the impairment of β-cell function after simultaneous pancreas-kidney transplantation[J]. PLoS One, 2019, 14(2):e0212547.
|
| 32 |
Rodelo-Haad C, Aguera ML, Martinez-Vaquera S, et al. Tyrosine-phosphatase and glutamate-decarboxylase antibodies after simultaneous pancreas kidney transplantation: do they have an impact on pancreas graft survival?[J]. Transplant Proc, 2015, 47(1):107-111.
|
| 33 |
Vendrame F, Pileggi A, Laughlin E, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells[J]. Diabetes, 2010, 59(4):947-957.
|
| 34 |
Ahmed S, Cerosaletti K, James E, et al. Standardizing T-cell biomarkers in type 1 diabetes: challenges and recent advances[J]. Diabetes, 2019, 68(7):1366-1379.
|
| 35 |
Roep BO, Stobbe I, Duinkerken G, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients[J]. 1999, 48(3):484-490.
|
| 36 |
Laughlin E, Burke G, Pugliese A, et al. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation[J]. Clin Immunol, 2008, 128(1):23-30.
|
| 37 |
Pinkse GG, Tysma OH, Bergen CA, et al. Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes[J]. Proc Natl Acad Sci U S A, 2005, 102(51):18425-18430.
|
| 38 |
Unger WW, Velthuis J, Abreu JR, et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers[J]. J Autoimmun, 2011, 37(3):151-159.
|
| 39 |
Hadrup SR, Bakker AH, Shu CJ, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers[J]. Nat Methods, 2009, 6(7):520-526.
|
| 40 |
Velthuis JH, Unger WW, Abreu JR, et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers[J]. Diabetes, 2010, 59(7):1721-1730.
|
| 41 |
Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells[J]. J Clin Invest, 2008, 118(5):1806-1814.
|